Alnylam Presented P-II Study Results of Cemdisiran for the Treatment of IgA Nephropathy at EMCHD 2022
Shots:
- The P-II study evaluates cemdisiran vs PBO in a ratio (2:1) in 31 patients aged ≥18 & ≤ 65yrs. with IgAN
- The results showed a 37% reduction in 24hr. UPCR @32wks. & showed an equivalent reduction in 24-hour urine total protein (36%), ≥50 percent reduction in 24-hour UPCR (32% vs 13%). The results were consistent with 24hr. urine data with the initial onset of treatment effect as early as 8wk. & remains stable over time, patients also achieved a 46% PBO-adjusted reduction from baseline in spot UPCR @32wks.
- The therapy was well tolerated with no AEs & no drug-related sev. AEs along with consistent proteinuria reduction were observed with 2EPs. The therapy showed favorable effects on different measures of proteinuria
Ref: Alnylam | Image: Alnylam
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
